Literature DB >> 8250645

Effects of the acetylcholinesterase inhibitor ENA-713 on ischemia-induced changes in acetylcholine and aromatic amine levels in the gerbil brain.

K Tanaka1, N Ogawa, M Asanuma, H Hirata, Y Kondo, N Nakayama, A Mori.   

Abstract

The effects of a new acetylcholinesterase inhibitor, ENA-713, on ischemia-induced changes in acetylcholine, monoamines, and their metabolites, were studied in the gerbil. ENA-713 (0.2 mg/kg) or saline was administered intraperitoneally to gerbils 30 min before induction of cerebral ischemia by bilateral carotid occlusion. Pretreatment with ENA-713 mitigated the ischemia-induced abnormalities of the cholinergic, dopaminergic and serotoninergic systems in the gerbil brain, although it had virtually no effect on acetylcholine, monoamines, or their metabolites in any region of the normal gerbil brain. These findings suggest that ENA-713 has beneficial effects against ischemia-induced cerebral disorders. Thus, ENA-713 seems to be promising as a preventive or therapeutic agent for cerebrovascular dementia due to cerebral ischemia and might be useful for the treatment of Alzheimer-type dementia which is associated with multiple neurotransmitter abnormalities in the brain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8250645

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  7 in total

1.  Relationship between locomotor activity and monoamines following single and double transient forebrain ischemia in gerbils.

Authors:  M E Haque; K Tanaka; N Ogawa
Journal:  Neurochem Res       Date:  2001-04       Impact factor: 3.996

2.  Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia.

Authors:  K Tanaka; N Ogawa; K Mizukawa; M Asanuma; Y Kondo; S Nishibayashi; A Mori
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

Review 3.  Rivastigmine. A review of its use in Alzheimer's disease.

Authors:  C M Spencer; S Noble
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

Review 4.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

6.  Post-ischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus.

Authors:  K Tanaka; K Mizukawa; N Ogawa; A Mori
Journal:  Neurochem Res       Date:  1995-06       Impact factor: 3.996

7.  Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.

Authors:  Kyung Won Park; Eun-Joo Kim; Hyun Jeong Han; Yong S Shim; Jae C Kwon; Bon D Ku; Kee Hyung Park; Hyon-Ah Yi; Kwang K Kim; Dong Won Yang; Ho-Won Lee; Heeyoung Kang; Oh Dae Kwon; SangYun Kim; Jae-Hyeok Lee; Eun Joo Chung; Sang-Won Park; Mee Young Park; Bora Yoon; Byeong C Kim; Sang Won Seo; Seong Hye Choi
Journal:  PLoS One       Date:  2017-08-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.